Axial Spondyloarthritis Drugs Market Report 2023 (Global Edition)
| Report ID: CMR286159 | SKU: CMR286159 | Edition: 7th Global Edition
| The base year for the calculation is 2023 and 2018 to 2023 will be historical period. The year 2023 will be estimated one while the forecasted data will be from year 2023 to 2028. When we deliver the report that time we updated report data till the purchase date. PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access. |
Share your contact details to receive free updated sample copy/pages of the recently published edition of Axial Spondyloarthritis Drugs Market Report 2023.
Key Insights from Axial Spondyloarthritis Drugs Market Report
According to Cognitive Market Research, the global Axial Spondylarthritis market size was USD 5.1 billion in 2022 and will grow and expand at a compound annual growth rate (CAGR) or growth rate of 7.2% from 2023 to 2030.
| Base Year | 2023 |
| Historical Data Time Period | 2018-2023 |
| Forecast Period | 2023-2030 |
| Global Axial Spondyloarthritis Drugs Market Compound Annual Growth Rate (CAGR) for 2023 to 2030 | 7.2% |
Axial Spondyloarthritis Drugs Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Axial Spondyloarthritis Drugs Market Report Description
Introduction of Axial Spondyloarthritis
With the increased adoption of digital technologies in the healthcare business, market estimatimation is projected to grow and expand considerably during the forecast period. The increase in studies and development conducted by prominent market players for generating innovative therapies for treating axial spondylarthritis may be attributed to the expansion of the worldwide axial spondylarthritis market. Furthermore, a rising general understanding of the ailment is anticcipate to drive market growth throughout the forecast period.
- For instance, AxSpA affects around 1.5 million Americans, with prevalence estimates fluctuating between 0.9% to 1.4%. axSpA often affects younger SpA patients, with a typical age of symptom start of 28 years.
(Source: www.ncbi.nlm.nih.gov/pmc/articles/PMC4032290/)
Despite a better knowledge of axSpA, there are still unmet requirements, most notably improving the protracted period between the onset of indications and proper therapy. Inflammation control is critical in the treatment of axial spondylarthritis.
Increase in R&D and Public Awareness of the Disease are Expected to Propel Market Growth
The increased emphasis of several biotechnological businesses on R&D activities is anticipated to propel the growth of the axial spondylarthritis (axSpA) industry. The development of innovative treatments, such as anti-Janus kinase therapy, anti-interleukin treatment, and anti-tumor necrosis factor medical treatment, by major market participants is significantly influencing the development of the axial spondylarthritis industry.
- Furthermore, the introduction of tumor necrosis factor inhibitors and interleukin 17 inhibitors signaled the beginning of a new era in pharmacological therapy.
(Source: pubmed.ncbi.nlm.nih.gov/25303306/)
Similarly, an increase in the number of authorized biosimilars is expected to drive the Axial Spondylarthritis (axSpA) industry throughout the forecast period.
Market Dynamics of Axial Spondyloarthritis
High Costs and Lack of Treatment Choices Hinder Market Growth
The primary limiting factors of prospective expansion for the axial spondyloarthritis treatment market during the anticipated period are a lack of treatment choices as well as the present high costs for these treatment solutions. The impact on adoption rates and increased diagnostic delay are restricting the growth of this market. The effectiveness of IL-17 inhibition is comparable to that of anti-TNF medications. Despite the treatment agents' equivalent efficacy, around half of the patients in clinical trials do not experience a meaningful change in primary outcomes. No oral alternatives are currently available, and finally, the high expense and difficulty in obtaining contemporary treatment regimens continue to be a significant obstacle for many patients.
Impact of COVID-19 on the Axial Spondylarthritis Market
As the incidence of COVID-19 cases increased globally, healthcare facilities focused all of their efforts on treating those infected. Although COVID-19 has a major influence on the respiratory tract, it has generated various issues concerning rheumatic illnesses, therapies, and the vulnerability or degree of viral infection. Patients with inflammatory diseases, which include spondyloarthritis (SpA), have discovered the COVID-19 pandemic is particularly challenging. Numerous researches have been conducted to measure the impact of a COVID-19 infection on people with rheumatic illnesses, but the findings aren't always consistent. In accordance with a study released by The Journal of Rheumatology in 2022 that polled answers from 4723 individuals suffering from SpA and 450 of their family contacts, the COVID-19 pandemic established many ambiguities regarding rheumatic illnesses or their treatment regarding the susceptibility along with the severity of the viral disease.
We have various report editions of Axial Spondyloarthritis Drugs Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Axial Spondyloarthritis Drugs Market Analysis
Global Axial Spondyloarthritis Drugs Market Report 2023 talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Axial Spondyloarthritis Drugs Industry growth. Axial Spondyloarthritis Drugs market has been segmented with the help of its Type, Drug class , and others. Axial Spondyloarthritis Drugs market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
Types Segment Analysis
According to Cognitive Market Research, Inflammation and bone formation characterized by ankylosing spondylitis, an uncommon form of AxSpA that impacts the spine and sacroiliac joints & and may result in stiffness and chronic pain, are boosting the market share throughout the projection period. 90% of AxSpA sufferers are considered to have ankylosing spondylitis.
Novartis International AG got a favorable CHMP opinion in March 2020, recommending approval of Cosentyx for the management of patients with active non-radiographic axial spondylarthritis. BE MOBILE 1 is the first clinical trial to evaluate the efficacy and safety of bimekizumab in individuals with active non-radiographic axial spondylarthritis (nr-axSpA).
- Ankylosing Spondylitis (AS)
- Non-radiographic Axial Spondyloarthritis (nr-axSpA)
Axial Spondyloarthritis Drugs Market Share (%) by Type in 2018-2030
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Axial Spondyloarthritis Drugs Industry. Request a Free Sample PDF!
Drug Class Segment Analysis
Nonsteroidal anti-inflammatory drugs (NSAID) will dominate the market during the forecast period because they are particularly effective at addressing the main axSpA signs and symptoms (pain and stiffness) and may also be capable of halting the structural spine's degradation. Nonsteroidal anti-inflammatory medications (NSAIDs) such as naproxen (Naprosyn) and indomethacin are popular therapies for axial spondyloarthritis.
Furthermore, because they are employed as the first line of therapy, new product introductions are anticipated to stimulate the treatment industry. For example, in July 2022, the European Commission authorized RINVOQ (upadacitinib) as an oral therapy for individuals with active non-radiographic axial spondylarthritis. As a result, the category is expected to increase significantly throughout the projection period.
- Non-steroidal Anti-inflammatory Drugs (NSAID)
- Glucocorticoids
- Anti-rheumatic drugs
- Others
Axial Spondyloarthritis Drugs Market Share (%) by Drug class in 2018-2030
The above Graph is for representation purposes only. This chart does not depict actual Market share. Please purchase the Axial Spondyloarthritis Drugs market report 2023 Edition by contacting our team.
The North American Axial Spondyloarthritis Market Dominate the Largest Share of Global Market
According to Cognitive Market Research, North America dominated the market in 2022 and accounted for a share of more than 39% of the global revenue due to several variables. The North American region dominates the market for Axial Spondylarthritis. Because of growing prevalence, awareness, and improved diagnosis, North America is expected to account for a sizable percentage of the worldwide market for axial spondylarthritis. Furthermore, the growth of the AxSpA business has been aided by favorable reimbursement practices in the United States and Canada. Furthermore, demand for these therapies has surged due to patients' ability to purchase expensive biologic drugs due to the availability of insurance coverage. Axial spondylarthritis affects millions of Americans, with prevalence estimates ranging from 0.9% to 1.4%. Axial spondylarthritis often affects younger spondylarthritis patients, with an average age of symptom start of 28 years.
Due to the enormous increase in the elderly population in countries such as China and India, Asia Pacific is expected to develop significantly during the projection period. The region's revenue increase is mostly due to the establishment of generic drug manufacturers and the expansion of medical facilities. The country's rise in scientific and technological activity can be ascribed to the country's expansion. Furthermore, rising healthcare spending, particularly in the developing area, and greater illness awareness are driving the overall local marketplace to a considerable extent.
The current report Scope analyzes Axial Spondyloarthritis Drugs Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Axial Spondyloarthritis Drugs Market Share (%) by Region (2018-2030)
The above graph is for illustrative purposes only. To learn more about geographical trends request the free sample pages. Contact US!
Author's Conclusion
Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.
The Global Axial Spondyloarthritis Drugs Market is witnessing significant growth in the near future.
In 2023, the Ankylosing Spondylitis (AS) segment accounted for noticeable share of global Axial Spondyloarthritis Drugs Market and is projected to experience significant growth in the near future.
The Non-steroidal Anti-inflammatory Drugs (NSAID) segment is expected to expand at the significant CAGR retaining position throughout the forecast period.
Some of the key companies Johnson and Johnson , Amgen and others are focusing on its strategy building model to strengthen its product portfolio and expand its business in the global market.
Author's Detail
Manjiri KanhereSenior Research Associate at Cognitive Market Research
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
Key Questions Answered By Axial Spondyloarthritis Drugs Market Report 2023
| Why Ankylosing Spondylitis (AS) have a significant impact on Axial Spondyloarthritis Drugs market? |
| What are the key factors affecting the Ankylosing Spondylitis (AS) and Non-radiographic Axial Spondyloarthritis (nr-axSpA) of Axial Spondyloarthritis Drugs Market? |
| What is the CAGR/Growth Rate of Non-steroidal Anti-inflammatory Drugs (NSAID) during the forecast period? |
| By type, which segment accounted for largest share of the global Axial Spondyloarthritis Drugs Market? |
| Which region is expected to dominate the global Axial Spondyloarthritis Drugs Market within the forecast period? |
- Measures to Explore Untapped Market
- Understanding Market Dynamics
- Understanding Changing Economics
- Competitors Market Share
- Global/Region/Country Level Analysis
- Identify Upcoming End Use Industries
- Global Price Trend Analysis
- Value Chain Analysis
- Customer Sentiment/Need Analysis
- Identification of Key Growth Segments
- Industry Upstream and Downstream Analysis
- Raw Material Sourcing and Cost Analysis
- Identify Key Customers Across Globe
- Concept Development and Market Testing
- Merger-Acquisition Strategy
- The research study and report are been made exclusively for an institution or person who is strategizing to build a business or strategically wants to expand certain portfolio.
- This report will help in analyzing complete market scenario across the globe who wish to expand their current business or is willing to invest in some profitable sector.
- This report will prove beneficial for person or an organization who wish to be updated regarding their business environment, consumers’ behaviour, and their requirements. The environment is constantly changing, and in such scenario, this report will help in understanding market parameters through 360-degree view.
- The report is thus ideal for KOL, CEO's, CFO's, directors, and others. It is also helpful to senior executives, business development managers, marketing managers, and consultants. Furthermore, government bodies, agencies and other kind of organizations can also leverage our report to understand market.
- Our objective for the Axial Spondyloarthritis Drugs market is to help in making imperative business decisions, securing investments, determining new business opportunities in the market. Further, the report helps to analyze overall marketing needs of customers, and avoid business failures.
- To know the potential market size and growth rate before launching a new product line. The report in a way helps in designing R&D budget wisely by estimating maximum total profit.
- To identify the Axial Spondyloarthritis Drugs market dynamics, industrial insights, and economic progression for critical information about the market conditions and specific business landscape.
- To assess the overall competitive landscape of a particular business sector and to provide complete analysis in regards with various external factors impacting the market growth.
- To create a strong foundation for building a strategy and foster insight into market conditions so that market players can make better business decisions. Besides, we aim to provide a complete portfolio of the major players involved the market.
- To define the scope which will further help in creating new products that will surpass the gap between current offerings and customers’ needs.
- To help in revealing significant clues concerning buying habits, regional culture, lifestyle, and population density that plays an integral role in shaping market behavior.
- To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the total market.
- Competitors Analysis: We provide data from the supplier side covering key details such as market share split among 1st tier, 2nd tier, and 3rd tier, Emerging Players, and Start-Ups. (whereas most of our competitors published data for top-tier companies)
- We provide market revenue share not only for Public listed companies but also the privately listed companies.
- Country Analysis: The Country level market split analysis is part of the report hence the data granularity is provided.
- We have been closely working with the Top 500 Fortune businesses, our clientele spanning 20+ industries. Our clientele is a mix of investors, manufacturers, end-users, distributors, etc. With our data subscription model (Athenaeum) 70% of clients have already subscribed/purchased reports for multiple years which helped us achieve unbelievable client retention statistics.
- Product + Service: In terms of the product we deliver the report access (PDF+ PPT+ EXCEL+ Cloud+ POWER BI) whereas in terms of service; we provide data support where a dedicated research analyst will be assigned and add-on benefits. (Whereas most of our competitors believe only in delivering the data/report and service and support remain questionable.)
- Credibility and Data Accuracy: We deliver accuracy close to 90-95% with the help of our in-house research team, freelancer, and industry expert network, sources present worldwide. This Data is backed up by strong research methodology
- What are our clients saying about our services.
Read more
Industry segmentation can be altred as per your needs. For example, we can proivde cross slipt between Ankylosing Spondylitis (AS) with Drug class, , additional country analysis, volume/consumption data, etc.
| Major Type Analysed |
|
| Major Drug class Analysed |
|
| Top Manufacturers Disclosed |
|
| Global, Regional and Country Analysis |
|
| Key Qualitative Information Covered |
|
Report scope is customizable as we have a huge database of Axial Spondyloarthritis Drugs industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
| Segmentation Level Customization | |
| Global level Data Customization | |
| Region level Data Customization | |
| Country level Data Customization | |
| Company Level | |
| Additional Data Analysis | |
| Additional Qualitative Data | |
| Additional Quantitative Data | |
| Service Level Customization | Report Format Alteration |
This chapter helps you to understand the importance of report and how we designed the report scope of Axial Spondyloarthritis Drugs market. As per your requirement we can also design the market scope as a customised report.
- 1.1 Global Axial Spondyloarthritis Drugs Industry Introduction
- 1.2 Objectives of the Study
- 1.3 USP of the Report
- 1.4 Who is this report for?
- 1.5 Designing of Market Scope
- 1.5.1 Axial Spondyloarthritis Drugs Market Segmentation
- 1.5.1 Axial Spondyloarthritis Drugs Market Regional Fragmentation
- 1.5.1 Axial Spondyloarthritis Drugs Market Players
- 1.6 Report Duration
- 1.7 List of Stakeholders
This chapter provides insights on our data collection and data validation process. It covers detailed information on wide range of sources referred during the study.
- 2.1 Axial Spondyloarthritis Drugs Market Report 2023 Research Methodology
- 2.2 Systematic Research Approach
- 2.2.1 Primary Research
- 2.2.1.1 Key Data from Primary
- 2.2.1.2 Primary Interviews with Experts
- 2.2.1.3 Key Industry Insights
- 2.2.1.4 Questionnaire
At Cognitive Market Research, we have designed questionnaire focused on Axial Spondyloarthritis Drugs Market for the statistical study. This questionnaire is the key part of our research methodology which is shared with number of Axial Spondyloarthritis Drugs industry experts of entire value chain, located across the globe. This study help us to gather accurate quantitative and qualitative data for the final report.
- 2.2.1.5 Breakdown of Primaries
- 2.2.2 Secondary Research
- 2.2.2.1 Key Data from Secondary
- 2.2.2.2 Paid Sources
- 2.2.2.3 Public Sources
- 2.2.1 Primary Research
- 2.3 Market Size Estimation
- 2.3.1 Top-Down Approach
- 2.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 2.3.1 Bottom-UP Approach
- 2.3.1.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 2.3.1 Top-Down Approach
- 2.4 Market Breakdown and Data Triangulation
- 2.5 Research Assumptions
The executive summary is an overview of a Axial Spondyloarthritis Drugs Market Report. In this chapter we have summarized the overall report data in snapshot format.
- 3.1 Global Axial Spondyloarthritis Drugs Market Size 2018 – 2030, (USD Million)
- 3.2 Global Axial Spondyloarthritis Drugs Value, Absolute & Opportunity Analysis
- 3.3 Global Axial Spondyloarthritis Drugs Market Y-o-Y Growth Rate Projection by Region (2023 - 2030)
- 3.4 Global Axial Spondyloarthritis Drugs Market Statistics 2023: Snapshot
This chapters incorporated product description overview and regional sales statistics for the year 2018-2030.
- 4.1 Axial Spondyloarthritis Drugs Introduction
- 4.2 Global Axial Spondyloarthritis Drugs Market Statistics by Regions (2018-2030)
- 4.2.1 North America Axial Spondyloarthritis Drugs Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
- 4.2.1.1 North America Axial Spondyloarthritis Drugs Market Size 2023 & 2030 (Revenue Comparison)
- 4.2.2 Europe Axial Spondyloarthritis Drugs Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
- 4.2.2.1 Europe Axial Spondyloarthritis Drugs Market Size 2023 & 2030 (Revenue Comparison)
- 4.2.3 Asia Pacific Axial Spondyloarthritis Drugs Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
- 4.2.3.1 Asia Pacific Axial Spondyloarthritis Drugs Market Size 2023 & 2030 (Revenue Comparison)
- 4.2.4 Latin America Axial Spondyloarthritis Drugs Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
- 4.2.4.1 Latin America Axial Spondyloarthritis Drugs Market Size 2023 & 2030 (Revenue Comparison)
- 4.2.5 Middle East and Africa Axial Spondyloarthritis Drugs Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
- 4.2.5.1 Middle East and Africa Axial Spondyloarthritis Drugs Market Size 2023 & 2030 (Revenue Comparison)
- 4.2.1 North America Axial Spondyloarthritis Drugs Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
- 4.3 Global Axial Spondyloarthritis Drugs Market Size (2018-2030)
- 4.3.1 Global Axial Spondyloarthritis Drugs Market Size 2023 & 2030 (Revenue Comparison)
- 4.3.2 Global Axial Spondyloarthritis Drugs Revenue Status and Outlook (2018-2030)
This chapter covers a competitive analysis of the global Axial Spondyloarthritis Drugs market, and it includes quantitative information such as revenue and market share of the manufacturers. The chapter also includes information regarding the strategies adopted by the manufacturers such as mergers, acquisitions, and new product launches.
- 5.1 Global Axial Spondyloarthritis Drugs Market Revenue and Share by Manufacturers (2018-2022)
- 5.2 Global Axial Spondyloarthritis Drugs Industry Mergers and Acquisition Analysis
- 5.3 Global Axial Spondyloarthritis Drugs New Launches Analysis
- 5.4 Company Categorization
- 5.5 Global Axial Spondyloarthritis Drugs Top Winning Strategies, by Manufacturers (2018-2022)
ESG analysis is the consideration of all factors in investment including environmental, social, and governance (ESG) factors. ESG integration is key part of the investment process. ESG analysis helps to measure company’s goals and progress when it comes to climate change, social improvement and good governance.
- 6.1 Overall Company’s Disclosure Score
This chapter helps you understand the Market Drivers, Market Restrain, Market Opportunity and Trends by each segment.
- 7.1 Axial Spondyloarthritis Drugs Industrial Dynamics
- 7.1.1 Global Axial Spondyloarthritis Drugs Market Drivers
- 7.1.2 Global Axial Spondyloarthritis Drugs Market Restrains
- 7.1.3 Global Axial Spondyloarthritis Drugs Market Opportunities
- 7.1.4 Global Axial Spondyloarthritis Drugs Market Trends
- 7.1.5 Global Axial Spondyloarthritis Drugs Technology (Road Map)
- 7.2 Axial Spondyloarthritis Drugs Market Attractiveness Analysis
- 7.1.1 Market Attractiveness Analysis by Type Segment
- 7.1.2 Market Attractiveness Analysis by Application Segment
- 7.3 PESTEL Analysis for Axial Spondyloarthritis Drugs Market
- 7.3.1 Political Factors
- 7.3.2 Economic Factors
- 7.3.3 Social Factors
- 7.3.4 Technological Factors
- 7.3.5 Legal Factors
- 7.3.6 Environmental Factors
- 7.4 Porter’s Five Forces Analysis for Axial Spondyloarthritis Drugs Market
- 7.4.1 Bargaining Power of Suppliers
- 7.4.2 Bargaining Power of Buyers
- 7.4.3 Threat of Substitutes
- 7.4.4 Threat of New Entrants
- 7.4.5 Degree of Competition
- 7.5 Axial Spondyloarthritis Drugs Market Product Life Cycle
- 7.6 COVID-19 Impact on Axial Spondyloarthritis Drugs Industry
- 7.4.1 Overall Impact of COVID-19 on Axial Spondyloarthritis Drugs Industry
- 7.4.2 Post COVID-19 Impact and Recovery Analysis
- 7.4.3 Influencing Factors
- 7.7 Consumer Preference Analysis for Axial Spondyloarthritis Drugs Market
- 7.8 Patent Analysis of Axial Spondyloarthritis Drugs
- 7.9 Axial Spondyloarthritis Drugs Industrial Chain Analysis
- 7.10 Manufacturing Cost Analysis
- 7.11 Supply Side Analysis
This segment of the report provides in-depth and pertinent information on every foremost player in the market through both primary and secondary research. The Company Basic Information, and Sales Area chapter includes ten or more key players, which are dominating the market. Each company profile includes demystifying professional information in a tabular format, which comprises the company’s official website, established year, market position, geographical presence, competitors, and contact information. Further, company profiling includes an in-detailed business overview, COVID-19 impact on the particular firm, product type specifications, revenue & market share, and recent developments done by the company for its inorganic development, such as mergers, strategic acquisitions, partnerships, and others. Besides, profiling includes the company’s investment in research and development activities. The recent innovative product launches, business expansion, investments done by the company in different markets, and other news are also available in the company profiling section. At last, it provides the company’s business strategy and SWOT analysis.
- 8.1 Johnson and Johnson
- 8.1.1 Johnson and Johnson Company Basic Information, and Sales Area
- 8.1.2 Johnson and Johnson Business Segment/ Overview
- 8.1.3 Johnson and Johnson Financials
- 8.1.3.1 Investment in Research and Development
- 8.1.3.2 Johnson and Johnson Sales Revenue (2018-2022)
- 8.1.3.3 Johnson and Johnson Market Share (2018-2022)
- 8.1.4 Johnson and Johnson Recent Developments
- 8.1.5 Johnson and Johnson Business Strategy
- 8.1.6 Johnson and Johnson Management Change
- 8.1.7 Johnson and Johnson
SWOT Analysis
- 8.1.7.1 Strength
- 8.1.7.2 Weakness
- 8.1.7.3 Opportunity
- 8.1.7.4 Threats
- 8.1.8 Johnson and Johnson COVID-19 Impact Analysis
- 8.2 AbbVie
- 8.2.1 AbbVie Company Basic Information, and Sales Area
- 8.2.2 AbbVie Business Segment/ Overview
- 8.2.3 AbbVie Financials
- 8.2.3.1 Investment in Research and Development
- 8.2.3.2 AbbVie Sales Revenue (2018-2022)
- 8.2.3.3 AbbVie Market Share (2018-2022)
- 8.2.4 AbbVie Recent Developments
- 8.2.5 AbbVie Business Strategy
- 8.2.6 AbbVie Management Change
- 8.2.7 AbbVie
SWOT Analysis
- 8.2.7.1 Strength
- 8.2.7.2 Weakness
- 8.2.7.3 Opportunity
- 8.2.7.4 Threats
- 8.2.8 AbbVie COVID-19 Impact Analysis
- 8.3 Amgen
- 8.3.1 Amgen Company Basic Information, and Sales Area
- 8.3.2 Amgen Business Segment/ Overview
- 8.3.3 Amgen Financials
- 8.3.3.1 Investment in Research and Development
- 8.3.3.2 Amgen Sales Revenue (2018-2022)
- 8.3.3.3 Amgen Market Share (2018-2022)
- 8.3.4 Amgen Recent Developments
- 8.3.5 Amgen Business Strategy
- 8.3.6 Amgen Management Change
- 8.3.7 Amgen
SWOT Analysis
- 8.3.7.1 Strength
- 8.3.7.2 Weakness
- 8.3.7.3 Opportunity
- 8.3.7.4 Threats
- 8.3.8 Amgen COVID-19 Impact Analysis
- 8.4 Novartis Pharmaceuticals Corporation
- 8.4.1 Novartis Pharmaceuticals Corporation Company Basic Information, and Sales Area
- 8.4.2 Novartis Pharmaceuticals Corporation Business Segment/ Overview
- 8.4.3 Novartis Pharmaceuticals Corporation Financials
- 8.4.3.1 Investment in Research and Development
- 8.4.3.2 Novartis Pharmaceuticals Corporation Sales Revenue (2018-2022)
- 8.4.3.3 Novartis Pharmaceuticals Corporation Market Share (2018-2022)
- 8.4.4 Novartis Pharmaceuticals Corporation Recent Developments
- 8.4.5 Novartis Pharmaceuticals Corporation Business Strategy
- 8.4.6 Novartis Pharmaceuticals Corporation Management Change
- 8.4.7 Novartis Pharmaceuticals Corporation
SWOT Analysis
- 8.4.7.1 Strength
- 8.4.7.2 Weakness
- 8.4.7.3 Opportunity
- 8.4.7.4 Threats
- 8.4.8 Novartis Pharmaceuticals Corporation COVID-19 Impact Analysis
- 8.5 Eli Lilly and Company
- 8.5.1 Eli Lilly and Company Company Basic Information, and Sales Area
- 8.5.2 Eli Lilly and Company Business Segment/ Overview
- 8.5.3 Eli Lilly and Company Financials
- 8.5.3.1 Investment in Research and Development
- 8.5.3.2 Eli Lilly and Company Sales Revenue (2018-2022)
- 8.5.3.3 Eli Lilly and Company Market Share (2018-2022)
- 8.5.4 Eli Lilly and Company Recent Developments
- 8.5.5 Eli Lilly and Company Business Strategy
- 8.5.6 Eli Lilly and Company Management Change
- 8.5.7 Eli Lilly and Company
SWOT Analysis
- 8.5.7.1 Strength
- 8.5.7.2 Weakness
- 8.5.7.3 Opportunity
- 8.5.7.4 Threats
- 8.5.8 Eli Lilly and Company COVID-19 Impact Analysis
- 8.6 UCB
- 8.6.1 UCB Company Basic Information, and Sales Area
- 8.6.2 UCB Business Segment/ Overview
- 8.6.3 UCB Financials
- 8.6.3.1 Investment in Research and Development
- 8.6.3.2 UCB Sales Revenue (2018-2022)
- 8.6.3.3 UCB Market Share (2018-2022)
- 8.6.4 UCB Recent Developments
- 8.6.5 UCB Business Strategy
- 8.6.6 UCB Management Change
- 8.6.7 UCB
SWOT Analysis
- 8.6.7.1 Strength
- 8.6.7.2 Weakness
- 8.6.7.3 Opportunity
- 8.6.7.4 Threats
- 8.6.8 UCB COVID-19 Impact Analysis
- 8.7 Kyowa Kirin
- 8.7.1 Kyowa Kirin Company Basic Information, and Sales Area
- 8.7.2 Kyowa Kirin Business Segment/ Overview
- 8.7.3 Kyowa Kirin Financials
- 8.7.3.1 Investment in Research and Development
- 8.7.3.2 Kyowa Kirin Sales Revenue (2018-2022)
- 8.7.3.3 Kyowa Kirin Market Share (2018-2022)
- 8.7.4 Kyowa Kirin Recent Developments
- 8.7.5 Kyowa Kirin Business Strategy
- 8.7.6 Kyowa Kirin Management Change
- 8.7.7 Kyowa Kirin
SWOT Analysis
- 8.7.7.1 Strength
- 8.7.7.2 Weakness
- 8.7.7.3 Opportunity
- 8.7.7.4 Threats
- 8.7.8 Kyowa Kirin COVID-19 Impact Analysis
- 8.8 AbbVie
- 8.8.1 AbbVie Company Basic Information, and Sales Area
- 8.8.2 AbbVie Business Segment/ Overview
- 8.8.3 AbbVie Financials
- 8.8.3.1 Investment in Research and Development
- 8.8.3.2 AbbVie Sales Revenue (2018-2022)
- 8.8.3.3 AbbVie Market Share (2018-2022)
- 8.8.4 AbbVie Recent Developments
- 8.8.5 AbbVie Business Strategy
- 8.8.6 AbbVie Management Change
- 8.8.7 AbbVie
SWOT Analysis
- 8.8.7.1 Strength
- 8.8.7.2 Weakness
- 8.8.7.3 Opportunity
- 8.8.7.4 Threats
- 8.8.8 AbbVie COVID-19 Impact Analysis
- 8.9 Acelyrin
- 8.9.1 Acelyrin Company Basic Information, and Sales Area
- 8.9.2 Acelyrin Business Segment/ Overview
- 8.9.3 Acelyrin Financials
- 8.9.3.1 Investment in Research and Development
- 8.9.3.2 Acelyrin Sales Revenue (2018-2022)
- 8.9.3.3 Acelyrin Market Share (2018-2022)
- 8.9.4 Acelyrin Recent Developments
- 8.9.5 Acelyrin Business Strategy
- 8.9.6 Acelyrin Management Change
- 8.9.7 Acelyrin
SWOT Analysis
- 8.9.7.1 Strength
- 8.9.7.2 Weakness
- 8.9.7.3 Opportunity
- 8.9.7.4 Threats
- 8.9.8 Acelyrin COVID-19 Impact Analysis
- 8.10 Pfizer
- 8.10.1 Pfizer Company Basic Information, and Sales Area
- 8.10.2 Pfizer Business Segment/ Overview
- 8.10.3 Pfizer Financials
- 8.10.3.1 Investment in Research and Development
- 8.10.3.2 Pfizer Sales Revenue (2018-2022)
- 8.10.3.3 Pfizer Market Share (2018-2022)
- 8.10.4 Pfizer Recent Developments
- 8.10.5 Pfizer Business Strategy
- 8.10.6 Pfizer Management Change
- 8.10.7 Pfizer
SWOT Analysis
- 8.10.7.1 Strength
- 8.10.7.2 Weakness
- 8.10.7.3 Opportunity
- 8.10.7.4 Threats
- 8.10.8 Pfizer COVID-19 Impact Analysis
- 8.11 Janssen Biotech
- 8.11.1 Janssen Biotech Company Basic Information, and Sales Area
- 8.11.2 Janssen Biotech Business Segment/ Overview
- 8.11.3 Janssen Biotech Financials
- 8.11.3.1 Investment in Research and Development
- 8.11.3.2 Janssen Biotech Sales Revenue (2018-2022)
- 8.11.3.3 Janssen Biotech Market Share (2018-2022)
- 8.11.4 Janssen Biotech Recent Developments
- 8.11.5 Janssen Biotech Business Strategy
- 8.11.6 Janssen Biotech Management Change
- 8.11.7 Janssen Biotech
SWOT Analysis
- 8.11.7.1 Strength
- 8.11.7.2 Weakness
- 8.11.7.3 Opportunity
- 8.11.7.4 Threats
- 8.11.8 Janssen Biotech COVID-19 Impact Analysis
- 8.12 Bristol-Myers Squibb Company
- 8.12.1 Bristol-Myers Squibb Company Company Basic Information, and Sales Area
- 8.12.2 Bristol-Myers Squibb Company Business Segment/ Overview
- 8.12.3 Bristol-Myers Squibb Company Financials
- 8.12.3.1 Investment in Research and Development
- 8.12.3.2 Bristol-Myers Squibb Company Sales Revenue (2018-2022)
- 8.12.3.3 Bristol-Myers Squibb Company Market Share (2018-2022)
- 8.12.4 Bristol-Myers Squibb Company Recent Developments
- 8.12.5 Bristol-Myers Squibb Company Business Strategy
- 8.12.6 Bristol-Myers Squibb Company Management Change
- 8.12.7 Bristol-Myers Squibb Company
SWOT Analysis
- 8.12.7.1 Strength
- 8.12.7.2 Weakness
- 8.12.7.3 Opportunity
- 8.12.7.4 Threats
- 8.12.8 Bristol-Myers Squibb Company COVID-19 Impact Analysis
- 8.13 Merck & Co
- 8.13.1 Merck & Co Company Basic Information, and Sales Area
- 8.13.2 Merck & Co Business Segment/ Overview
- 8.13.3 Merck & Co Financials
- 8.13.3.1 Investment in Research and Development
- 8.13.3.2 Merck & Co Sales Revenue (2018-2022)
- 8.13.3.3 Merck & Co Market Share (2018-2022)
- 8.13.4 Merck & Co Recent Developments
- 8.13.5 Merck & Co Business Strategy
- 8.13.6 Merck & Co Management Change
- 8.13.7 Merck & Co
SWOT Analysis
- 8.13.7.1 Strength
- 8.13.7.2 Weakness
- 8.13.7.3 Opportunity
- 8.13.7.4 Threats
- 8.13.8 Merck & Co COVID-19 Impact Analysis
- 8.14 Takeda Pharmaceutical Company
- 8.14.1 Takeda Pharmaceutical Company Company Basic Information, and Sales Area
- 8.14.2 Takeda Pharmaceutical Company Business Segment/ Overview
- 8.14.3 Takeda Pharmaceutical Company Financials
- 8.14.3.1 Investment in Research and Development
- 8.14.3.2 Takeda Pharmaceutical Company Sales Revenue (2018-2022)
- 8.14.3.3 Takeda Pharmaceutical Company Market Share (2018-2022)
- 8.14.4 Takeda Pharmaceutical Company Recent Developments
- 8.14.5 Takeda Pharmaceutical Company Business Strategy
- 8.14.6 Takeda Pharmaceutical Company Management Change
- 8.14.7 Takeda Pharmaceutical Company
SWOT Analysis
- 8.14.7.1 Strength
- 8.14.7.2 Weakness
- 8.14.7.3 Opportunity
- 8.14.7.4 Threats
- 8.14.8 Takeda Pharmaceutical Company COVID-19 Impact Analysis
- 8.15 FunPep Co Ltd
- 8.15.1 FunPep Co Ltd Company Basic Information, and Sales Area
- 8.15.2 FunPep Co Ltd Business Segment/ Overview
- 8.15.3 FunPep Co Ltd Financials
- 8.15.3.1 Investment in Research and Development
- 8.15.3.2 FunPep Co Ltd Sales Revenue (2018-2022)
- 8.15.3.3 FunPep Co Ltd Market Share (2018-2022)
- 8.15.4 FunPep Co Ltd Recent Developments
- 8.15.5 FunPep Co Ltd Business Strategy
- 8.15.6 FunPep Co Ltd Management Change
- 8.15.7 FunPep Co Ltd
SWOT Analysis
- 8.15.7.1 Strength
- 8.15.7.2 Weakness
- 8.15.7.3 Opportunity
- 8.15.7.4 Threats
- 8.15.8 FunPep Co Ltd COVID-19 Impact Analysis
- 8.16 Abbott
- 8.16.1 Abbott Company Basic Information, and Sales Area
- 8.16.2 Abbott Business Segment/ Overview
- 8.16.3 Abbott Financials
- 8.16.3.1 Investment in Research and Development
- 8.16.3.2 Abbott Sales Revenue (2018-2022)
- 8.16.3.3 Abbott Market Share (2018-2022)
- 8.16.4 Abbott Recent Developments
- 8.16.5 Abbott Business Strategy
- 8.16.6 Abbott Management Change
- 8.16.7 Abbott
SWOT Analysis
- 8.16.7.1 Strength
- 8.16.7.2 Weakness
- 8.16.7.3 Opportunity
- 8.16.7.4 Threats
- 8.16.8 Abbott COVID-19 Impact Analysis
- 8.17 GlaxoSmithKline plc
- 8.17.1 GlaxoSmithKline plc Company Basic Information, and Sales Area
- 8.17.2 GlaxoSmithKline plc Business Segment/ Overview
- 8.17.3 GlaxoSmithKline plc Financials
- 8.17.3.1 Investment in Research and Development
- 8.17.3.2 GlaxoSmithKline plc Sales Revenue (2018-2022)
- 8.17.3.3 GlaxoSmithKline plc Market Share (2018-2022)
- 8.17.4 GlaxoSmithKline plc Recent Developments
- 8.17.5 GlaxoSmithKline plc Business Strategy
- 8.17.6 GlaxoSmithKline plc Management Change
- 8.17.7 GlaxoSmithKline plc
SWOT Analysis
- 8.17.7.1 Strength
- 8.17.7.2 Weakness
- 8.17.7.3 Opportunity
- 8.17.7.4 Threats
- 8.17.8 GlaxoSmithKline plc COVID-19 Impact Analysis
- 8.18 Merz Pharma
- 8.18.1 Merz Pharma Company Basic Information, and Sales Area
- 8.18.2 Merz Pharma Business Segment/ Overview
- 8.18.3 Merz Pharma Financials
- 8.18.3.1 Investment in Research and Development
- 8.18.3.2 Merz Pharma Sales Revenue (2018-2022)
- 8.18.3.3 Merz Pharma Market Share (2018-2022)
- 8.18.4 Merz Pharma Recent Developments
- 8.18.5 Merz Pharma Business Strategy
- 8.18.6 Merz Pharma Management Change
- 8.18.7 Merz Pharma
SWOT Analysis
- 8.18.7.1 Strength
- 8.18.7.2 Weakness
- 8.18.7.3 Opportunity
- 8.18.7.4 Threats
- 8.18.8 Merz Pharma COVID-19 Impact Analysis
- 8.19 Medytox
- 8.19.1 Medytox Company Basic Information, and Sales Area
- 8.19.2 Medytox Business Segment/ Overview
- 8.19.3 Medytox Financials
- 8.19.3.1 Investment in Research and Development
- 8.19.3.2 Medytox Sales Revenue (2018-2022)
- 8.19.3.3 Medytox Market Share (2018-2022)
- 8.19.4 Medytox Recent Developments
- 8.19.5 Medytox Business Strategy
- 8.19.6 Medytox Management Change
- 8.19.7 Medytox
SWOT Analysis
- 8.19.7.1 Strength
- 8.19.7.2 Weakness
- 8.19.7.3 Opportunity
- 8.19.7.4 Threats
- 8.19.8 Medytox COVID-19 Impact Analysis
- 8.20 Smith+Nephew
- 8.20.1 Smith+Nephew Company Basic Information, and Sales Area
- 8.20.2 Smith+Nephew Business Segment/ Overview
- 8.20.3 Smith+Nephew Financials
- 8.20.3.1 Investment in Research and Development
- 8.20.3.2 Smith+Nephew Sales Revenue (2018-2022)
- 8.20.3.3 Smith+Nephew Market Share (2018-2022)
- 8.20.4 Smith+Nephew Recent Developments
- 8.20.5 Smith+Nephew Business Strategy
- 8.20.6 Smith+Nephew Management Change
- 8.20.7 Smith+Nephew
SWOT Analysis
- 8.20.7.1 Strength
- 8.20.7.2 Weakness
- 8.20.7.3 Opportunity
- 8.20.7.4 Threats
- 8.20.8 Smith+Nephew COVID-19 Impact Analysis
- 8.21 Sanofi
- 8.21.1 Sanofi Company Basic Information, and Sales Area
- 8.21.2 Sanofi Business Segment/ Overview
- 8.21.3 Sanofi Financials
- 8.21.3.1 Investment in Research and Development
- 8.21.3.2 Sanofi Sales Revenue (2018-2022)
- 8.21.3.3 Sanofi Market Share (2018-2022)
- 8.21.4 Sanofi Recent Developments
- 8.21.5 Sanofi Business Strategy
- 8.21.6 Sanofi Management Change
- 8.21.7 Sanofi
SWOT Analysis
- 8.21.7.1 Strength
- 8.21.7.2 Weakness
- 8.21.7.3 Opportunity
- 8.21.7.4 Threats
- 8.21.8 Sanofi COVID-19 Impact Analysis
- 8.22 Novartis AG
- 8.22.1 Novartis AG Company Basic Information, and Sales Area
- 8.22.2 Novartis AG Business Segment/ Overview
- 8.22.3 Novartis AG Financials
- 8.22.3.1 Investment in Research and Development
- 8.22.3.2 Novartis AG Sales Revenue (2018-2022)
- 8.22.3.3 Novartis AG Market Share (2018-2022)
- 8.22.4 Novartis AG Recent Developments
- 8.22.5 Novartis AG Business Strategy
- 8.22.6 Novartis AG Management Change
- 8.22.7 Novartis AG
SWOT Analysis
- 8.22.7.1 Strength
- 8.22.7.2 Weakness
- 8.22.7.3 Opportunity
- 8.22.7.4 Threats
- 8.22.8 Novartis AG COVID-19 Impact Analysis
- 8.23 Teva Pharmaceutical Industries Ltd
- 8.23.1 Teva Pharmaceutical Industries Ltd Company Basic Information, and Sales Area
- 8.23.2 Teva Pharmaceutical Industries Ltd Business Segment/ Overview
- 8.23.3 Teva Pharmaceutical Industries Ltd Financials
- 8.23.3.1 Investment in Research and Development
- 8.23.3.2 Teva Pharmaceutical Industries Ltd Sales Revenue (2018-2022)
- 8.23.3.3 Teva Pharmaceutical Industries Ltd Market Share (2018-2022)
- 8.23.4 Teva Pharmaceutical Industries Ltd Recent Developments
- 8.23.5 Teva Pharmaceutical Industries Ltd Business Strategy
- 8.23.6 Teva Pharmaceutical Industries Ltd Management Change
- 8.23.7 Teva Pharmaceutical Industries Ltd
SWOT Analysis
- 8.23.7.1 Strength
- 8.23.7.2 Weakness
- 8.23.7.3 Opportunity
- 8.23.7.4 Threats
- 8.23.8 Teva Pharmaceutical Industries Ltd COVID-19 Impact Analysis
- 8.24 LGM Pharma
- 8.24.1 LGM Pharma Company Basic Information, and Sales Area
- 8.24.2 LGM Pharma Business Segment/ Overview
- 8.24.3 LGM Pharma Financials
- 8.24.3.1 Investment in Research and Development
- 8.24.3.2 LGM Pharma Sales Revenue (2018-2022)
- 8.24.3.3 LGM Pharma Market Share (2018-2022)
- 8.24.4 LGM Pharma Recent Developments
- 8.24.5 LGM Pharma Business Strategy
- 8.24.6 LGM Pharma Management Change
- 8.24.7 LGM Pharma
SWOT Analysis
- 8.24.7.1 Strength
- 8.24.7.2 Weakness
- 8.24.7.3 Opportunity
- 8.24.7.4 Threats
- 8.24.8 LGM Pharma COVID-19 Impact Analysis
- 8.25 Lannett
- 8.25.1 Lannett Company Basic Information, and Sales Area
- 8.25.2 Lannett Business Segment/ Overview
- 8.25.3 Lannett Financials
- 8.25.3.1 Investment in Research and Development
- 8.25.3.2 Lannett Sales Revenue (2018-2022)
- 8.25.3.3 Lannett Market Share (2018-2022)
- 8.25.4 Lannett Recent Developments
- 8.25.5 Lannett Business Strategy
- 8.25.6 Lannett Management Change
- 8.25.7 Lannett
SWOT Analysis
- 8.25.7.1 Strength
- 8.25.7.2 Weakness
- 8.25.7.3 Opportunity
- 8.25.7.4 Threats
- 8.25.8 Lannett COVID-19 Impact Analysis
- 8.26 NorthStar Rx LLC
- 8.26.1 NorthStar Rx LLC Company Basic Information, and Sales Area
- 8.26.2 NorthStar Rx LLC Business Segment/ Overview
- 8.26.3 NorthStar Rx LLC Financials
- 8.26.3.1 Investment in Research and Development
- 8.26.3.2 NorthStar Rx LLC Sales Revenue (2018-2022)
- 8.26.3.3 NorthStar Rx LLC Market Share (2018-2022)
- 8.26.4 NorthStar Rx LLC Recent Developments
- 8.26.5 NorthStar Rx LLC Business Strategy
- 8.26.6 NorthStar Rx LLC Management Change
- 8.26.7 NorthStar Rx LLC
SWOT Analysis
- 8.26.7.1 Strength
- 8.26.7.2 Weakness
- 8.26.7.3 Opportunity
- 8.26.7.4 Threats
- 8.26.8 NorthStar Rx LLC COVID-19 Impact Analysis
- 8.27 Par Pharmaceutical
- 8.27.1 Par Pharmaceutical Company Basic Information, and Sales Area
- 8.27.2 Par Pharmaceutical Business Segment/ Overview
- 8.27.3 Par Pharmaceutical Financials
- 8.27.3.1 Investment in Research and Development
- 8.27.3.2 Par Pharmaceutical Sales Revenue (2018-2022)
- 8.27.3.3 Par Pharmaceutical Market Share (2018-2022)
- 8.27.4 Par Pharmaceutical Recent Developments
- 8.27.5 Par Pharmaceutical Business Strategy
- 8.27.6 Par Pharmaceutical Management Change
- 8.27.7 Par Pharmaceutical SWOT Analysis
- 8.27.7.1 Strength
- 8.27.7.2 Weakness
- 8.27.7.3 Opportunity
- 8.27.7.4 Threats
- 8.27.8 Par Pharmaceutical COVID-19 Impact Analysis
This chapter covers in-detailed insights regarding type segments to understand consumer interests and provide a revenue stream for each type. Type segment analysis help in making a better business decision to maximize profitability by focusing resources on those market type that are relatively favorable to their goals.
- 9.1 Detailed Qualitative Analysis
- 9.2 Global Axial Spondyloarthritis Drugs Revenue and Share (%) by Type (2018-2030)
- 9.2.1 Ankylosing Spondylitis (AS)
Market Size
- 9.2.1.1 Global Ankylosing Spondylitis (AS) Market Share and Revenue (USD Million) for 2018-2030
- 9.2.1.2 Axial Spondyloarthritis Drugs Market Market Size 2023 & 2030 (Revenue Comparison)
- 9.2.1.3 Axial Spondyloarthritis Drugs Market for Ankylosing Spondylitis (AS) , by Country (2021 Vs 2024)
- 9.2.2 Non-radiographic Axial Spondyloarthritis (nr-axSpA) Market Size
- 9.2.2.1 Global Non-radiographic Axial Spondyloarthritis (nr-axSpA) Market Share and Revenue (USD Million) for 2018-2030
- 9.2.2.2 Axial Spondyloarthritis Drugs Market Market Size 2023 & 2030 (Revenue Comparison)
- 9.2.2.3 Axial Spondyloarthritis Drugs Market for Non-radiographic Axial Spondyloarthritis (nr-axSpA), by Country (2021 Vs 2024)
- 9.2.1 Ankylosing Spondylitis (AS)
Market Size
This chapter covers in-detailed insights regarding type segments to understand consumer interests and provide a revenue stream for each type. Type segment analysis help in making a better business decision to maximize profitability by focusing resources on those market type that are relatively favorable to their goals.
- 10.1 Detailed Qualitative Analysis
- 10.2 Global Axial Spondyloarthritis Drugs Revenue and Share (%) by Drug class (2018-2030)
- 10.2.1 Non-steroidal Anti-inflammatory Drugs (NSAID)
Market Size
- 10.2.1.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Market Share and Revenue (USD Million) for 2018-2030
- 10.2.1.2 Axial Spondyloarthritis Drugs Market Market Size 2023 & 2030 (Revenue Comparison)
- 10.2.1.3 Axial Spondyloarthritis Drugs Market for Non-steroidal Anti-inflammatory Drugs (NSAID) , by Country (2021 Vs 2024)
- 10.2.2 Glucocorticoids
Market Size
- 10.2.2.1 Global Glucocorticoids Market Share and Revenue (USD Million) for 2018-2030
- 10.2.2.2 Axial Spondyloarthritis Drugs Market Market Size 2023 & 2030 (Revenue Comparison)
- 10.2.2.3 Axial Spondyloarthritis Drugs Market for Glucocorticoids , by Country (2021 Vs 2024)
- 10.2.3 Anti-rheumatic drugs
Market Size
- 10.2.3.1 Global Anti-rheumatic drugs Market Share and Revenue (USD Million) for 2018-2030
- 10.2.3.2 Axial Spondyloarthritis Drugs Market Market Size 2023 & 2030 (Revenue Comparison)
- 10.2.3.3 Axial Spondyloarthritis Drugs Market for Anti-rheumatic drugs , by Country (2021 Vs 2024)
- 10.2.4 Others Market Size
- 10.2.4.1 Global Others Market Share and Revenue (USD Million) for 2018-2030
- 10.2.4.2 Axial Spondyloarthritis Drugs Market Market Size 2023 & 2030 (Revenue Comparison)
- 10.2.4.3 Axial Spondyloarthritis Drugs Market for Others, by Country (2021 Vs 2024)
- 10.2.1 Non-steroidal Anti-inflammatory Drugs (NSAID)
Market Size
This chapter categorizes detailed perceptions into an application segment based on end users’ needs, and preferences to understand their requirements and purchasing patterns effectively. It analyzes the current trends of the market that mainly consists of information related to new product use, trends in consumer demand, and available close substitutes of the product.
- 11.1 Detailed Qualitative Analysis
- 11.2 Global Axial Spondyloarthritis Drugs Market Revenue by Region (2018-2030)
- 11.2 Global Axial Spondyloarthritis Drugs Market Share (%) by Region (2018-2030)
- 12.1 North America
- 12.1.1 North America Axial Spondyloarthritis Drugs Market Trends and Analysis
- 12.1.2 North America Axial Spondyloarthritis Drugs Market by Country, 2018-2030
- 12.1.3 North America Axial Spondyloarthritis Drugs Market Attractiveness Analysis by Country
- 12.2 North America Axial Spondyloarthritis Drugs Market Size (2018-2030)
- 12.2.1 North America Axial Spondyloarthritis Drugs Market (USD Million) by Type (2018-2030)
- 12.2.1.1 Ankylosing Spondylitis (AS)
- 12.2.1.1.1 North America Ankylosing Spondylitis (AS) Market Share and Revenue (USD Million) for 2018-2030
- 12.2.1.2 Non-radiographic Axial Spondyloarthritis (nr-axSpA)
- 12.2.1.2.1 North America Non-radiographic Axial Spondyloarthritis (nr-axSpA) Market Share and Revenue (USD Million) for 2018-2030
- 12.2.1.1 Ankylosing Spondylitis (AS)
- 12.2.2 North America Axial Spondyloarthritis Drugs Market (USD Million) by Drug class (2018-2030)
- 12.2.2.1 Non-steroidal Anti-inflammatory Drugs (NSAID)
- 12.2.2.1.1 North America Non-steroidal Anti-inflammatory Drugs (NSAID) Market Share and Revenue (USD Million) for 2018-2030
- 12.2.2.2 Glucocorticoids
- 12.2.2.2.1 North America Glucocorticoids Market Share and Revenue (USD Million) for 2018-2030
- 12.2.2.3 Anti-rheumatic drugs
- 12.2.2.3.1 North America Anti-rheumatic drugs Market Share and Revenue (USD Million) for 2018-2030
- 12.2.2.4 Others
- 12.2.2.4.1 North America Others Market Share and Revenue (USD Million) for 2018-2030
- 12.2.2.1 Non-steroidal Anti-inflammatory Drugs (NSAID)
- 12.2.1 North America Axial Spondyloarthritis Drugs Market (USD Million) by Type (2018-2030)
- 13.1 Europe
- 13.1.1 Europe Axial Spondyloarthritis Drugs Market Trends and Analysis
- 13.1.2 Europe Axial Spondyloarthritis Drugs Market by Country, 2018-2030
- 13.1.3 Europe Axial Spondyloarthritis Drugs Market Attractiveness Analysis by Country
- 13.2 Europe Axial Spondyloarthritis Drugs Market Size (2018-2030)
- 13.2.1 Europe Axial Spondyloarthritis Drugs Market (USD Million) by Type (2018-2030)
- 13.2.1.1 Ankylosing Spondylitis (AS)
- 13.2.1.1.1 Europe Ankylosing Spondylitis (AS) Market Share and Revenue (USD Million) for 2018-2030
- 13.2.1.2 Non-radiographic Axial Spondyloarthritis (nr-axSpA)
- 13.2.1.2.1 Europe Non-radiographic Axial Spondyloarthritis (nr-axSpA) Market Share and Revenue (USD Million) for 2018-2030
- 13.2.1.1 Ankylosing Spondylitis (AS)
- 13.2.2 Europe Axial Spondyloarthritis Drugs Market (USD Million) by Drug class (2018-2030)
- 13.2.2.1 Non-steroidal Anti-inflammatory Drugs (NSAID)
- 13.2.2.1.1 Europe Non-steroidal Anti-inflammatory Drugs (NSAID) Market Share and Revenue (USD Million) for 2018-2030
- 13.2.2.2 Glucocorticoids
- 13.2.2.2.1 Europe Glucocorticoids Market Share and Revenue (USD Million) for 2018-2030
- 13.2.2.3 Anti-rheumatic drugs
- 13.2.2.3.1 Europe Anti-rheumatic drugs Market Share and Revenue (USD Million) for 2018-2030
- 13.2.2.4 Others
- 13.2.2.4.1 Europe Others Market Share and Revenue (USD Million) for 2018-2030
- 13.2.2.1 Non-steroidal Anti-inflammatory Drugs (NSAID)
- 13.2.1 Europe Axial Spondyloarthritis Drugs Market (USD Million) by Type (2018-2030)
- 14.1 Asia Pacific
- 14.1.1 Asia Pacific Axial Spondyloarthritis Drugs Market Trends and Analysis
- 14.1.2 Asia Pacific Axial Spondyloarthritis Drugs Market by Country, 2018-2030
- 14.1.3 Asia Pacific Axial Spondyloarthritis Drugs Market Attractiveness Analysis by Country
- 14.2 Asia Pacific Axial Spondyloarthritis Drugs Market Size (2018-2030)
- 14.2.1 Asia Pacific Axial Spondyloarthritis Drugs Market (USD Million) by Type (2018-2030)
- 14.2.1.1 Ankylosing Spondylitis (AS)
- 14.2.1.1.1 Asia Pacific Ankylosing Spondylitis (AS) Market Share and Revenue (USD Million) for 2018-2030
- 14.2.1.2 Non-radiographic Axial Spondyloarthritis (nr-axSpA)
- 14.2.1.2.1 Asia Pacific Non-radiographic Axial Spondyloarthritis (nr-axSpA) Market Share and Revenue (USD Million) for 2018-2030
- 14.2.1.1 Ankylosing Spondylitis (AS)
- 14.2.2 Asia Pacific Axial Spondyloarthritis Drugs Market (USD Million) by Drug class (2018-2030)
- 14.2.2.1 Non-steroidal Anti-inflammatory Drugs (NSAID)
- 14.2.2.1.1 Asia Pacific Non-steroidal Anti-inflammatory Drugs (NSAID) Market Share and Revenue (USD Million) for 2018-2030
- 14.2.2.2 Glucocorticoids
- 14.2.2.2.1 Asia Pacific Glucocorticoids Market Share and Revenue (USD Million) for 2018-2030
- 14.2.2.3 Anti-rheumatic drugs
- 14.2.2.3.1 Asia Pacific Anti-rheumatic drugs Market Share and Revenue (USD Million) for 2018-2030
- 14.2.2.4 Others
- 14.2.2.4.1 Asia Pacific Others Market Share and Revenue (USD Million) for 2018-2030
- 14.2.2.1 Non-steroidal Anti-inflammatory Drugs (NSAID)
- 14.2.1 Asia Pacific Axial Spondyloarthritis Drugs Market (USD Million) by Type (2018-2030)
- 15.1 Latin America
- 15.1.1 Latin America Axial Spondyloarthritis Drugs Market Trends and Analysis
- 15.1.2 Latin America Axial Spondyloarthritis Drugs Market by Country, 2018-2030
- 15.1.3 Latin America Axial Spondyloarthritis Drugs Market Attractiveness Analysis by Country
- 15.2 Latin America Axial Spondyloarthritis Drugs Market Size (2018-2030)
- 15.2.1 Latin America Axial Spondyloarthritis Drugs Market (USD Million) by Type (2018-2030)
- 15.2.1.1 Ankylosing Spondylitis (AS)
- 15.2.1.1.1 Latin America Ankylosing Spondylitis (AS) Market Share and Revenue (USD Million) for 2018-2030
- 15.2.1.2 Non-radiographic Axial Spondyloarthritis (nr-axSpA)
- 15.2.1.2.1 Latin America Non-radiographic Axial Spondyloarthritis (nr-axSpA) Market Share and Revenue (USD Million) for 2018-2030
- 15.2.1.1 Ankylosing Spondylitis (AS)
- 15.2.2 Latin America Axial Spondyloarthritis Drugs Market (USD Million) by Drug class (2018-2030)
- 15.2.2.1 Non-steroidal Anti-inflammatory Drugs (NSAID)
- 15.2.2.1.1 Latin America Non-steroidal Anti-inflammatory Drugs (NSAID) Market Share and Revenue (USD Million) for 2018-2030
- 15.2.2.2 Glucocorticoids
- 15.2.2.2.1 Latin America Glucocorticoids Market Share and Revenue (USD Million) for 2018-2030
- 15.2.2.3 Anti-rheumatic drugs
- 15.2.2.3.1 Latin America Anti-rheumatic drugs Market Share and Revenue (USD Million) for 2018-2030
- 15.2.2.4 Others
- 15.2.2.4.1 Latin America Others Market Share and Revenue (USD Million) for 2018-2030
- 15.2.2.1 Non-steroidal Anti-inflammatory Drugs (NSAID)
- 15.2.1 Latin America Axial Spondyloarthritis Drugs Market (USD Million) by Type (2018-2030)
- 16.1 Middle East and Africa
- 16.1.1 Middle East and Africa Axial Spondyloarthritis Drugs Market Trends and Analysis
- 16.1.2 Middle East and Africa Axial Spondyloarthritis Drugs Market by Country, 2018-2030
- 16.1.3 Middle East and Africa Axial Spondyloarthritis Drugs Market Attractiveness Analysis by Country
- 16.2 Middle East and Africa Axial Spondyloarthritis Drugs Market Size (2018-2030)
- 16.2.1 Middle East and Africa Axial Spondyloarthritis Drugs Market (USD Million) by Type (2018-2030)
- 16.2.1.1 Ankylosing Spondylitis (AS)
- 16.2.1.1.1 Middle East and Africa Ankylosing Spondylitis (AS) Market Share and Revenue (USD Million) for 2018-2030
- 16.2.1.2 Non-radiographic Axial Spondyloarthritis (nr-axSpA)
- 16.2.1.2.1 Middle East and Africa Non-radiographic Axial Spondyloarthritis (nr-axSpA) Market Share and Revenue (USD Million) for 2018-2030
- 16.2.1.1 Ankylosing Spondylitis (AS)
- 16.2.2 Middle East and Africa Axial Spondyloarthritis Drugs Market (USD Million) by Drug class (2018-2030)
- 16.2.2.1 Non-steroidal Anti-inflammatory Drugs (NSAID)
- 16.2.2.1.1 Middle East and Africa Non-steroidal Anti-inflammatory Drugs (NSAID) Market Share and Revenue (USD Million) for 2018-2030
- 16.2.2.2 Glucocorticoids
- 16.2.2.2.1 Middle East and Africa Glucocorticoids Market Share and Revenue (USD Million) for 2018-2030
- 16.2.2.3 Anti-rheumatic drugs
- 16.2.2.3.1 Middle East and Africa Anti-rheumatic drugs Market Share and Revenue (USD Million) for 2018-2030
- 16.2.2.4 Others
- 16.2.2.4.1 Middle East and Africa Others Market Share and Revenue (USD Million) for 2018-2030
- 16.2.2.1 Non-steroidal Anti-inflammatory Drugs (NSAID)
- 16.2.1 Middle East and Africa Axial Spondyloarthritis Drugs Market (USD Million) by Type (2018-2030)
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Axial Spondyloarthritis Drugs market
- 17.1 Key Takeaways
- 17.2 Analyst Point of View
- 17.3 Assumptions
Top Companies Market Share in Axial Spondyloarthritis Drugs Industry: (In no particular order of Rank)
- Johnson and Johnson
- AbbVie
- Amgen
- Novartis Pharmaceuticals Corporation
- Eli Lilly and Company
- UCB
- Kyowa Kirin
- AbbVie
- Acelyrin
- Pfizer
- Janssen Biotech
- Bristol-Myers Squibb Company
- Merck & Co
- Takeda Pharmaceutical Company
- FunPep Co Ltd
- Abbott
- GlaxoSmithKline plc
- Merz Pharma
- Medytox
- Smith+Nephew
- Sanofi
- Novartis AG
- Teva Pharmaceutical Industries Ltd
- LGM Pharma
- Lannett
- NorthStar Rx LLC
- Par Pharmaceutical
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables..
Competitive Landscape of Axial Spondylarthritis Market
The market for Axial Spondylarthritis is a highly dynamic and diversified competitive environment. It includes various suppliers, ranging from large multinational enterprises to smaller specialized organizations. Market participants are also undertaking various organic or inorganic strategic approaches to strengthen and expand their global footprint, with significant market developments including new Material portfolios, contractual deals, mergers and acquisitions, capital expenditure, higher investments, and strategic alliances with other organizations. Businesses are also coming up with marketing strategies such as digital marketing, social media influencing, and content marketing to increase their scope of profit earnings. Because of automation and technological advancement, businesses compete fiercely to deliver innovative products.
- January 2022: UCB, a global biopharmaceutical firm, revealed good top-line interim analysis findings demonstrating that the Phase 3 BE MOBILE 1 trial met the main and all ranking secondary objectives in January 2022. BE MOBILE 1 is the first clinical trial to evaluate the efficacy and safety of bimekizumab in individuals with active nr-axSpA.
- January 2022: AbbVie announced in January 2022 that it had submitted applications for approval of upadacitinib (RINVOQ, 15 mg once daily) to the US FDA and the EMA for the treatment of adults with active nr-axSpA with indications of inflammation who had not responded adequately to nonsteroidal anti-inflammatory drugs (NSAIDs). The Phase 3 SELECT-AXIS 2 (Study 2) clinical experiment assists the applicants.
- April 2022: Ampersand Health and UCB announced a collaboration in April 2022 to aid patients with axSpA. The two firms will support Project Nightingale, an ongoing investigation performed by the RNHRD in Bath. The project aims to help axSpA patients manage their symptoms and improve their quality of life.
(Source:ampersandhealth.co.uk/news-events/press-release-ampersand-health-x-ucb/)
- March 2022: According to trial data published in the Journal of Rheumatology in March 2022, Ixekizumab effectively decreased or stopped the development of radiographic axial spondyloarthritis (r-axSpA) throughout a 2-year treatment period.
(Source:pubmed.ncbi.nlm.nih.gov/34853086/)
Research Methodology Implemented by Author
- 1.1 Axial Spondyloarthritis Drugs Market Report 2023 Research Methodology
- 1.2 Systematic Research Approach
- 1.2.1 Primary Research for Axial Spondyloarthritis Drugs Market
- 1.2.1.1 Key Data from Primary
- 1.2.1.2 Primary Interviews with Experts
- 1.2.1.3 Key Industry Insights
- 1.2.1.4 Questionnaire for Axial Spondyloarthritis Drugs Market
- 1.2.1.5 Breakdown of Primaries
- 1.2.2 Secondary Research for Axial Spondyloarthritis Drugs Market
- 1.2.2.1 Key Data from Secondary
- 1.2.2.2 Paid Sources
- 1.2.2.3 Public Sources
- 1.3 Market Size Estimation for Axial Spondyloarthritis Drugs Market
- 1.3.1 Top-Down Approach
- 1.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 1.3.2 Bottom-UP Approach
- 1.3.2.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 1.3.1 Top-Down Approach
- 1.4 Market Breakdown and Data Triangulation
- 1.5 Research Assumptions for Axial Spondyloarthritis Drugs Market
Frequently Asked Questions (FAQs)
We have listed the discounted pricing including Tax/es. Please kindly note, report pricing and data inclusion depends upon the selection of the report edition + user license. Hence, please kindly choose an appropriate user license depending upon the number of users or employees are going to utilize the report data or the as per the need of the data/consultation services. To know more contact us.
Global Report Edition includes data about 5 major regions and a total of 36 countries. Please refer to the Table of Contents tab. If you require customized data our research team will assist you and provide you with an exclusive report edition delivery. You can also purchase regional and country-level data edition/s. Please get in contact with us prior to making a purchase sales@cognitivemarketresearch.com.
The regional report edition will help you get the data specific to the to selected region from the drop down.
The country specific report edition and the respective table of content will be delivered to you as per your enquiry or you can refer the following link for the same.
We have listed the discounted pricing including Tax/es. Please kindly note, report pricing and data inclusion depends upon the selection of the report edition + user license. Hence, please kindly choose an appropriate user license depending upon the number of users or employees are going to utilize the report data or the as per the need of the data/consultation services. To know more contact us.
Global Report Edition includes data about 5 major regions and a total of 36 countries. Please refer to the Table of Contents tab. If you require customized data our research team will assist you and provide you with an exclusive report edition delivery. You can also purchase regional and country-level data edition/s. Please get in contact with us prior to making a purchase sales@cognitivemarketresearch.com.
The regional report edition will help you get the data specific to the to selected region from the drop down.
The country specific report edition and the respective table of content will be delivered to you as per your enquiry or you can refer the following link for the same.
